Johnson-Davis Kamisha L, Truong Jannine G, Fleckenstein Annette E, Wilkins Diana G
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112-9457, USA.
J Pharmacol Exp Ther. 2004 May;309(2):578-86. doi: 10.1124/jpet.103.062695. Epub 2004 Jan 27.
Previous studies demonstrated that tolerance to the long-term neurotoxic effects of methamphetamine on dopamine neurons could be induced by pretreating with multiple injections of escalating doses of methamphetamine. The mechanism(s) underlying this tolerance phenomenon is unknown. Some recent studies suggested that aberrant vesicular monoamine transporter-2 (VMAT-2) and dopamine transporter function contribute to neurotoxic effects of methamphetamine. Hence, the purpose of this study was to explore the role of the VMAT-2 and dopamine transporter in the induction of tolerance to the longterm persistent dopaminergic deficits caused by methamphetamine. A second purpose was to investigate the potential role of hyperthermia and alterations in brain methamphetamine distribution in this tolerance. Results revealed that the methamphetamine pretreatment regimen attenuated both the acute methamphetamine-induced decrease in VMAT-2 function 2 h after the methamphetamine challenge administration and its resulting persistent dopamine deficits without attenuating the acute methamphetamine-induced decreases in dopamine transporter uptake. Furthermore, pretreatment with methamphetamine prior to a high-dose methamphetamine challenge administration also attenuated the acute methamphetamine-induced redistribution of VMAT-2 immunoreactivity within the nerve terminal. This protection was not due to alterations in concentration of methamphetamine in the brain because both the methamphetamine- and saline-pretreated rats had similar amounts of methamphetamine and amphetamine at 30 min to 2 h after the last methamphetamine challenge injection. In summary, these data are the first to demonstrate an association between the prevention of acute alterations in vesicular dopamine uptake and the development of tolerance to the neurotoxic effects of methamphetamine.
先前的研究表明,通过多次注射递增剂量的甲基苯丙胺进行预处理,可以诱导对甲基苯丙胺对多巴胺能神经元的长期神经毒性作用产生耐受性。这种耐受现象背后的机制尚不清楚。最近的一些研究表明,异常的囊泡单胺转运体2(VMAT-2)和多巴胺转运体功能促成了甲基苯丙胺的神经毒性作用。因此,本研究的目的是探讨VMAT-2和多巴胺转运体在诱导对甲基苯丙胺所致长期持续性多巴胺能缺陷的耐受性中的作用。第二个目的是研究体温过高和脑内甲基苯丙胺分布改变在这种耐受性中的潜在作用。结果显示,甲基苯丙胺预处理方案减轻了甲基苯丙胺激发给药后2小时急性甲基苯丙胺诱导的VMAT-2功能下降及其导致的持续性多巴胺能缺陷,而没有减轻急性甲基苯丙胺诱导的多巴胺转运体摄取减少。此外,在高剂量甲基苯丙胺激发给药前用甲基苯丙胺预处理也减轻了急性甲基苯丙胺诱导的神经末梢内VMAT-2免疫反应性的重新分布。这种保护作用并非由于脑内甲基苯丙胺浓度的改变,因为在最后一次甲基苯丙胺激发注射后30分钟至2小时,甲基苯丙胺预处理组和生理盐水预处理组的大鼠脑内甲基苯丙胺和苯丙胺的含量相似。总之,这些数据首次证明了预防囊泡多巴胺摄取的急性改变与对甲基苯丙胺神经毒性作用的耐受性发展之间的关联。